Loading...
XETR
BIO
Market cap1.78bUSD
Apr 17, Last price  
42.40EUR
1D
0.00%
1Q
1.44%
Jan 2017
166.67%
Name

Biotest AG

Chart & Performance

D1W1MN
P/E
17.07
P/S
3.17
EPS
2.48
Div Yield, %
0.09%
Shrs. gr., 5y
—
Rev. gr., 5y
11.33%
Revenues
685m
+32.65%
217,851,000000422,956,000440,191,000412,482,000422,027,000439,967,000500,800,000582,000,000589,600,000553,100,000378,100,000400,300,000419,100,000484,200,000515,600,000516,100,000684,600,000
Net income
127m
P
5,854,00000028,119,00028,020,00039,485,00048,149,00033,408,00032,000,00019,200,000-82,500,000-45,800,000-3,500,000181,700,000-4,700,000-31,400,000-63,300,000-31,600,000127,000,000
CFO
-3m
L-93.33%
25,291,00028,317,00026,307,00032,509,00034,489,00031,682,00077,828,00072,278,00034,726,000-7,200,000-11,400,00038,100,00065,900,00034,300,000-50,000,000-33,600,000-16,700,00033,900,000-40,500,000-2,700,000
Dividend
May 08, 20240.04 EUR/sh
Earnings
May 05, 2025

Profile

Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. As of January 21, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.
URL
https://www.biotest.com/
IPO date
Oct 14, 1987
Employees
2,307
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
684,600
32.65%
516,100
0.10%
Cost of revenue
551,500
522,400
Unusual Expense (Income)
NOPBT
133,100
(6,300)
NOPBT Margin
19.44%
Operating Taxes
(20,700)
800
Tax Rate
NOPAT
153,800
(7,100)
Net income
127,000
-501.90%
(31,600)
-50.08%
Dividends
(800)
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
260,100
9,400
Long-term debt
487,500
593,900
Deferred revenue
Other long-term liabilities
97,000
135,600
Net debt
601,200
481,600
Cash flow
Cash from operating activities
(2,700)
(40,500)
CAPEX
(33,400)
(29,300)
Cash from investing activities
1,300
(37,000)
Cash from financing activities
(6,800)
89,600
FCF
(28,300)
(62,200)
Balance
Cash
118,500
136,600
Long term investments
27,900
(14,900)
Excess cash
112,170
95,895
Stockholders' equity
279,100
151,300
Invested Capital
1,173,530
982,305
ROIC
14.27%
ROCE
10.35%
EV
Common stock shares outstanding
39,571
39,571
Price
Market cap
EV
EBITDA
169,000
29,500
EV/EBITDA
Interest
40,000
19,700
Interest/NOPBT
30.05%